Effects of bacillus calmette-guerin polysaccharide nucleotide by different ways of intervention on airway inflammation and airway hyperresponsiveness in asthmatic mouse model
Hua Jiang,Kefang Lai,Lu Shen,Yin Xi,Yandong Nan,Faguang Jin
DOI: https://doi.org/10.3877/cma.j.issn.1674-6902.2018.03.002
2018-01-01
Abstract:Objective To investigate the effect of BCG-PSN by different methods of intervention on airway inflammation and airway reactivity in asthmatic mouse model. Methods Balb/c mice were sensitized by ovalbumin to establish the asthmatic mouse model and divided into normal group, asthma group and BCG-PSN intervention group.For BCG-PSN intervention group, the dose of BCG-PSN was 20 μg/60 μl, all of which were intervened after the final excitation, and according to the intervention methods, the intervention group was subdivided into the intramuscular injection group ( im) and intranasal administration after anesthesia group (in). Airway responsiveness was measured by Buxco company's mice overall volume scanning method in 2 d, 14 d respectively after final excitation, which was demonstrated by enhanced breathing intermittence (Enhanced Pause, Penh) under different concentrations of methacholine stimulation. Airway reactivity was evaluated by PC100 ( Mch excitation concentration when the increased airway reactivity is 2 times of physiological saline ( NS) ) and Penh/NS% comprehensively. The bronchoalveolar lavage fluid was collected and the ratio of eosinophils was counted in the smears stained with haematoxylin and eosin, and with pathological examination of lung tissue. Results BCG-PSN (im) group PC100 was (9.48±3.06) mg/ml in early stages, compared with asthma group (4.79±1.51)mg/ml, P＜0.05, in the later stages PC100 was (4.96±1.88) mg/ml, (5.55± 3.11) mg/ml for asthma group, there was no statistically significant differences in these two groups, for BCG-PSN(in) group, PC100 is (12.39±4.89)mg/ml,(9.19±2.35)mg/ml in early and later stages respectively, compared with the asthma group, had statistical significance (P＜0.05), and in later stages, BCG-PSN(in) group was significantly higher than BCG-PSN(im) group. For the Eos% in BALF, asthma group was (40.73± 6.01)%, and BCG-PSN(im) group was (35.65±4.27)%, there was no significant difference between these two groups, BCG-PSN(in) group was (30.98±5.45)%, which is significantly lower than the asthma group (P＜0.05). Conclusion BCG-PSN has a therapeutic effect on the asthmatic mice. The effects of BCG-PSN by intranasal administration after anesthesia are equivalent to or even superior to the effects by intramuscular administration, BCG-PSN by intratracheal administration is expected to become a new way for prevention and therapy on asthma.